Jing Tang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1187665/publications.pdf

Version: 2024-02-01

125106 78623 6,930 95 35 77 h-index citations g-index papers 126 126 126 11885 docs citations times ranked citing authors all docs

| # | Article | IF | CITATIONS |
|----|--|-------------|-----------|
| 1 | Minimal information for chemosensitivity assays (MICHA): a next-generation pipeline to enable the FAIRification of drug screening experiments. Briefings in Bioinformatics, 2022, 23, . | 3.2 | 7 |
| 2 | A community challenge for a pancancer drug mechanism of action inference from perturbational profile data. Cell Reports Medicine, 2022, 3, 100492. | 3. 3 | 33 |
| 3 | SynergyFinder Plus: Toward Better Interpretation and Annotation of Drug Combination Screening Datasets. Genomics, Proteomics and Bioinformatics, 2022, 20, 587-596. | 3.0 | 159 |
| 4 | Prognosis Stratification Tools in Early-Stage Endometrial Cancer: Could We Improve Their Accuracy?. Cancers, 2022, 14, 912. | 1.7 | 4 |
| 5 | Bayes in Wonderland! Predictive Supervised Classification Inference Hits Unpredictability. Mathematics, 2022, 10, 828. | 1.1 | 1 |
| 6 | Antitumoral Effect of Plocabulin in High Grade Serous Ovarian Carcinoma Cell Line Models. Frontiers in Oncology, 2022, 12, 862321. | 1.3 | 1 |
| 7 | The ENDS of assumptions: an online tool for the epistemic non-parametric drug–response scoring. Bioinformatics, 2022, 38, 3132-3133. | 1.8 | O |
| 8 | Bipartite network models to design combination therapies in acute myeloid leukaemia. Nature Communications, 2022, 13, 2128. | 5.8 | 15 |
| 9 | Using BERT to identify drug-target interactions from whole PubMed. BMC Bioinformatics, 2022, 23, . | 1.2 | 6 |
| 10 | Exploration of databases and methods supporting drug repurposing: a comprehensive survey. Briefings in Bioinformatics, 2021, 22, 1656-1678. | 3.2 | 66 |
| 11 | Anticancer drug synergy prediction in understudied tissues using transfer learning. Journal of the American Medical Informatics Association: JAMIA, 2021, 28, 42-51. | 2.2 | 51 |
| 12 | CD73 contributes to antiâ€inflammatory properties of afferent lymphatic endothelial cells in humans and mice. European Journal of Immunology, 2021, 51, 231-246. | 1.6 | 12 |
| 13 | A three-term recurrence relation for accurate evaluation of transition probabilities of the simple birth-and-death process. BIT Numerical Mathematics, 2021, 61, 561-585. | 1.0 | 0 |
| 14 | Identification of Celecoxib-Targeted Proteins Using Label-Free Thermal Proteome Profiling on Rat Hippocampus. Molecular Pharmacology, 2021, 99, 308-318. | 1.0 | 9 |
| 15 | Common pitfalls and recommendations for using machine learning to detect and prognosticate for COVID-19 using chest radiographs and CT scans. Nature Machine Intelligence, 2021, 3, 199-217. | 8.3 | 607 |
| 16 | Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS oVâ€2 infection in vitro. British Journal of Pharmacology, 2021, 178, 2339-2350. | 2.7 | 74 |
| 17 | Network-based modeling of herb combinations in traditional Chinese medicine. Briefings in Bioinformatics, 2021, 22, . | 3.2 | 62 |
| 18 | RNA atlas of human bacterial pathogens uncovers stress dynamics linked to infection. Nature Communications, 2021, 12, 3282. | 5.8 | 33 |

| # | Article | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | DrugComb update: a more comprehensive drug sensitivity data repository and analysis portal. Nucleic Acids Research, 2021, 49, W174-W184. | 6.5 | 54 |
| 20 | S100 Calcium Binding Protein Family Members Associate With Poor Patient Outcome and Response to Proteasome Inhibition in Multiple Myeloma. Frontiers in Cell and Developmental Biology, 2021, 9, 723016. | 1.8 | 5 |
| 21 | Comparative analysis of molecular fingerprints in prediction of drug combination effects. Briefings in Bioinformatics, 2021, 22, . | 3.2 | 47 |
| 22 | Network-guided identification of cancer-selective combinatorial therapies in ovarian cancer. Briefings in Bioinformatics, 2021, 22, . | 3.2 | 13 |
| 23 | Application of microfluidic chips in anticancer drug screening. Bosnian Journal of Basic Medical Sciences, 2021, , . | 0.6 | 4 |
| 24 | Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma. Blood Advances, 2021, 5, 4125-4139. | 2.5 | 6 |
| 25 | Combination Therapy with Fluoxetine and the Nucleoside Analog GS-441524 Exerts Synergistic Antiviral Effects against Different SARS-CoV-2 Variants In Vitro. Pharmaceutics, 2021, 13, 1400. | 2.0 | 35 |
| 26 | Seasonal Variation in the Brain $\hat{l}\frac{1}{4}$ -Opioid Receptor Availability. Journal of Neuroscience, 2021, 41, 1265-1273. | 1.7 | 14 |
| 27 | Vascular adhesion protein-1 defines a unique subpopulation of human hematopoietic stem cells and regulates their proliferation. Cellular and Molecular Life Sciences, 2021, 78, 7851-7872. | 2.4 | 1 |
| 28 | Drug repurposing for COVID-19 using graph neural network and harmonizing multiple evidence. Scientific Reports, $2021, 11, 23179$. | 1.6 | 28 |
| 29 | Eribulin activity in soft tissue sarcoma monolayer and three-dimensional cell line models: could the combination with other drugs improve its antitumoral effect?. Cancer Cell International, 2021, 21, 646. | 1.8 | 6 |
| 30 | Multi-parametric single cell evaluation defines distinct drug responses in healthy hematologic cells that are retained in corresponding malignant cell types. Haematologica, 2020, 105, 1527-1538. | 1.7 | 19 |
| 31 | Chloroplot: An Online Program for the Versatile Plotting of Organelle Genomes. Frontiers in Genetics, 2020, 11, 576124. | 1.1 | 135 |
| 32 | Unsupervised Learning and Multipartite Network Models: A Promising Approach for Understanding Traditional Medicine. Frontiers in Pharmacology, 2020, 11, 1319. | 1.6 | 29 |
| 33 | Can We Assume the Gene Expression Profile as a Proxy for Signaling Network Activity?. Biomolecules, 2020, 10, 850. | 1.8 | 8 |
| 34 | Network pharmacology modeling identifies synergistic Aurora B and ZAK interaction in triple-negative breast cancer. Npj Systems Biology and Applications, 2019, 5, 20. | 1.4 | 32 |
| 35 | Drug combination sensitivity scoring facilitates the discovery of synergistic and efficacious drug combinations in cancer. PLoS Computational Biology, 2019, 15, e1006752. | 1.5 | 106 |
| 36 | DrugComb: an integrative cancer drug combination data portal. Nucleic Acids Research, 2019, 47, W43-W51. | 6.5 | 153 |

| # | Article | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Making Sense of the Epigenome Using Data Integration Approaches. Frontiers in Pharmacology, 2019, 10, 126. | 1.6 | 58 |
| 38 | Predicting Meridian in Chinese traditional medicine using machine learning approaches. PLoS Computational Biology, 2019, 15, e1007249. | 1.5 | 41 |
| 39 | Combined gene essentiality scoring improves the prediction of cancer dependency maps. EBioMedicine, 2019, 50, 67-80. | 2.7 | 18 |
| 40 | Loss-of-function mutations with circadian rhythm regulator Per1/Per2 lead to premature ovarian insufficiencyâ€. Biology of Reproduction, 2019, 100, 1066-1072. | 1.2 | 23 |
| 41 | Predicting Meridian in Chinese traditional medicine using machine learning approaches. , 2019, 15, e1007249. | | 0 |
| 42 | Predicting Meridian in Chinese traditional medicine using machine learning approaches. , 2019, 15, e1007249. | | 0 |
| 43 | Predicting Meridian in Chinese traditional medicine using machine learning approaches., 2019, 15, e1007249. | | 0 |
| 44 | Predicting Meridian in Chinese traditional medicine using machine learning approaches. , 2019, 15, e1007249. | | 0 |
| 45 | Patient-Customized Drug Combination Prediction and Testing for T-cell Prolymphocytic Leukemia Patients. Cancer Research, 2018, 78, 2407-2418. | 0.4 | 60 |
| 46 | Methods for High-throughput Drug Combination Screening and Synergy Scoring. Methods in Molecular Biology, 2018, 1711, 351-398. | 0.4 | 140 |
| 47 | Drug Target Commons: A Community Effort to Build a Consensus Knowledge Base for Drug-Target Interactions. Cell Chemical Biology, 2018, 25, 224-229.e2. | 2.5 | 124 |
| 48 | Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling. Leukemia, 2018, 32, 774-787. | 3.3 | 75 |
| 49 | Drug Target Commons 2.0: a community platform for systematic analysis of drug–target interaction profiles. Database: the Journal of Biological Databases and Curation, 2018, 2018, 1-13. | 1.4 | 36 |
| 50 | Multi-Parametric Single Cell Profiling Defines Distinct Drug Responses in Healthy Hematological Cell Lineages That Are Retained in Corresponding Malignant Cell Types. Blood, 2018, 132, 264-264. | 0.6 | 5 |
| 51 | Predictive Response Biomarkers for BET Inhibitors in AML. Blood, 2018, 132, 2749-2749. | 0.6 | 2 |
| 52 | Eltrombopag Promotes Megakaryocyte Survival and Signaling in the Presence of Specific Cytotoxic Agents. Blood, 2018, 132, 3836-3836. | 0.6 | 0 |
| 53 | Systematic drug sensitivity testing reveals synergistic growth inhibition by dasatinib or mTOR inhibitors with paclitaxel in ovarian granulosa cell tumor cells. Gynecologic Oncology, 2017, 144, 621-630. | 0.6 | 26 |
| 54 | JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell–induced protection of AML. Blood, 2017, 130, 789-802. | 0.6 | 90 |

| # | Article | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Treatment of novel IL17A inhibitor in glioblastoma implementing 3rd generation co-culture cell line and patient-derived tumor model. European Journal of Pharmacology, 2017, 803, 24-38. | 1.7 | 7 |
| 56 | SynergyFinder: a web application for analyzing drug combination dose–response matrix data. Bioinformatics, 2017, 33, 2413-2415. | 1.8 | 403 |
| 57 | The inconvenience of data of convenience: computational research beyond post-mortem analyses. Nature Methods, 2017, 14, 937-938. | 9.0 | 9 |
| 58 | A Community Challenge for Inferring Genetic Predictors of Gene Essentialities through Analysis of a Functional Screen of Cancer Cell Lines. Cell Systems, 2017, 5, 485-497.e3. | 2.9 | 19 |
| 59 | Seed-effect modeling improves the consistency of genome-wide loss-of-function screens and identifies synthetic lethal vulnerabilities in cancer cells. Genome Medicine, 2017, 9, 51. | 3.6 | 12 |
| 60 | Informatics Approaches for Predicting, Understanding, and Testing Cancer Drug Combinations. Methods in Molecular Biology, 2017, 1636, 485-506. | 0.4 | 11 |
| 61 | Abstract A26: Prediction of synergistic anticancer drug combinations by integrating chemical and genetic screens., 2017,,. | | 0 |
| 62 | A three-year survey of the antimicrobial resistance of microorganisms at a Chinese hospital. Experimental and Therapeutic Medicine, 2016, 11, 731-736. | 0.8 | 7 |
| 63 | Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis. Nature Communications, 2016, 7, 12460. | 5.8 | 73 |
| 64 | Metastasis associated in colon cancer 1 (MACC1) promotes growth and metastasis processes of colon cancer cells. European Review for Medical and Pharmacological Sciences, 2016, 20, 2825-34. | 0.5 | 23 |
| 65 | From drug response profiling to target addiction scoring in cancer cell models. DMM Disease Models and Mechanisms, 2015, 8, 1255-1264. | 1.2 | 13 |
| 66 | What is synergy? The Saariselkà agreement revisited. Frontiers in Pharmacology, 2015, 6, 181. | 1.6 | 147 |
| 67 | Toward more realistic drug-target interaction predictions. Briefings in Bioinformatics, 2015, 16, 325-337. | 3.2 | 331 |
| 68 | Network pharmacology applications to map the unexplored target space and therapeutic potential of natural products. Natural Product Reports, 2015, 32, 1249-1266. | 5.2 | 331 |
| 69 | TIMMA-R: an R package for predicting synergistic multi-targeted drug combinations in cancer cell lines or patient-derived samples. Bioinformatics, 2015, 31, 1866-1868. | 1.8 | 15 |
| 70 | Systematic Mapping of Kinase Addiction Combinations in Breast Cancer Cells by Integrating Drug Sensitivity and Selectivity Profiles. Chemistry and Biology, 2015, 22, 1144-1155. | 6.2 | 22 |
| 71 | Prediction of human population responses to toxic compounds by a collaborative competition. Nature Biotechnology, 2015, 33, 933-940. | 9.4 | 88 |
| 72 | A Bayesian Predictive Model for Clustering Data of Mixed Discrete and Continuous Type. IEEE Transactions on Pattern Analysis and Machine Intelligence, 2015, 37, 489-498. | 9.7 | 14 |

| # | Article | IF | Citations |
|----|---|-----|-----------|
| 73 | Stromal-Derived Factors Modulate Ex Vivo Drug Responses of Primary Acute Myeloid Leukemia Cells. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S8-S9. | 0.2 | O |
| 74 | Searching for Drug Synergy in Complex Dose–Response Landscapes Using an Interaction Potency Model. Computational and Structural Biotechnology Journal, 2015, 13, 504-513. | 1.9 | 485 |
| 75 | Abstract 3746: Novel therapeutic possibilities for chemorefractory ovarian cancer patients identified by functional ex vivo drug sensitivity testing of primary cells from ascites. , 2015, , . | | 1 |
| 76 | JAK1/2 and BCL2 Inhibitors Synergize to Counter-Act Bone Marrow Stromal Cell-Induced Protection of AML. Blood, 2015, 126, 867-867. | 0.6 | 0 |
| 77 | Network Pharmacology Strategies Toward Multi-Target Anticancer Therapies: From Computational Models to Experimental Design Principles. Current Pharmaceutical Design, 2014, 20, 23-36. | 0.9 | 115 |
| 78 | Making Sense of Large-Scale Kinase Inhibitor Bioactivity Data Sets: A Comparative and Integrative Analysis. Journal of Chemical Information and Modeling, 2014, 54, 735-743. | 2.5 | 284 |
| 79 | Phosphorylation of human La protein at Ser ³⁶⁶ by casein kinase II contributes to hepatitis B virus replication and expression <i>in vitro</i> . Journal of Viral Hepatitis, 2013, 20, 24-33. | 1.0 | 11 |
| 80 | Target Inhibition Networks: Predicting Selective Combinations of Druggable Targets to Block Cancer Survival Pathways. PLoS Computational Biology, 2013, 9, e1003226. | 1.5 | 84 |
| 81 | Genomic, Transcriptomic, and Lipidomic Profiling Highlights the Role of Inflammation in Individuals With Low High-density Lipoprotein Cholesterol. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 847-857. | 1.1 | 35 |
| 82 | Abstract 5220: Identifying AML-specific key targeted drugs using high-throughput drug sensitivity and resistance testing profiles of AML cells , $2013, \dots$ | | 0 |
| 83 | Phospholipids and insulin resistance in psychosis: a lipidomics study of twin pairs discordant for schizophrenia. Genome Medicine, 2012, 4, 1. | 3.6 | 106 |
| 84 | Metabolome in schizophrenia and other psychotic disorders: a general population-based study. Genome Medicine, 2011, 3, 19. | 3.6 | 131 |
| 85 | Association of Lipidome Remodeling in the Adipocyte Membrane with Acquired Obesity in Humans. PLoS Biology, 2011, 9, e1000623. | 2.6 | 213 |
| 86 | ELEVATED SERUM SPHINGOMYELIN ASSOCIATES WITH REDUCED GRAY MATTER DENSITY: EVIDENCE FROM TWINS DISCORDANT FOR SCHIZOPHRENIA. Schizophrenia Research, 2010, 117, 370-371. | 1.1 | 0 |
| 87 | Identifying Currents in the Gene Pool for Bacterial Populations Using an Integrative Approach. PLoS Computational Biology, 2009, 5, e1000455. | 1.5 | 112 |
| 88 | Integrating post-genomic approaches as a strategy to advance our understanding of health and disease. Genome Medicine, 2009, 1, 35. | 3.6 | 23 |
| 89 | Bayesian Clustering of Fuzzy Feature Vectors Using a Quasi-Likelihood Approach. IEEE Transactions on Pattern Analysis and Machine Intelligence, 2009, 31, 74-85. | 9.7 | 8 |
| 90 | Hyper-Recombination, Diversity, and Antibiotic Resistance in Pneumococcus. Science, 2009, 324, 1454-1457. | 6.0 | 164 |

| # | Article | IF | CITATIONS |
|----|--|-----|-----------|
| 91 | Enhanced Bayesian modelling in BAPS software for learning genetic structures of populations. BMC Bioinformatics, 2008, 9, 539. | 1.2 | 760 |
| 92 | T-BAPS: A Bayesian Statistical Tool for Comparison of Microbial Communities Using Terminal-restriction Fragment Length Polymorphism (T-RFLP) Data. Statistical Applications in Genetics and Molecular Biology, 2007, 6, Article30. | 0.2 | 5 |
| 93 | Bayesian analysis of population structure based on linked molecular information. Mathematical Biosciences, 2007, 205, 19-31. | 0.9 | 214 |
| 94 | Quantitative changes in collagen levels following 830-nm diode laser welding., 1998, 22, 207-211. | | 21 |
| 95 | Quantitative changes in collagen levels following 830â€nm diode laser welding. Lasers in Surgery and Medicine, 1998, 22, 207-211. | 1.1 | 2 |